Summary
This large-scale genome-wide association study of over 40,000 bipolar disorder cases identified 64 associated genomic loci and implicated 15 genes as potential druggable targets, including HTR6, MCHR1, DCLK3 and FURIN. The findings reveal enrichment of risk alleles in synaptic signalling and genes expressed in the prefrontal cortex and hippocampus, with significant overlap with targets of existing antipsychotics and other psychiatric medications. The work advances understanding of bipolar disorder's biological aetiology and provides leads for therapeutic development and functional follow-up studies.
UK applicability
These genetic findings have potential relevance to UK psychiatric research and clinical practice, particularly in understanding biological mechanisms of bipolar disorder across European ancestry populations. However, direct application requires validation in diverse populations and integration with UK healthcare systems and treatment pathways.
Key measures
Genomic loci associated with bipolar disorder; gene expression correlation; enrichment in synaptic signalling pathways; genetic correlation between bipolar disorder type I and II
Outcomes reported
The study identified 64 genomic loci associated with bipolar disorder through analysis of 41,917 cases and 371,549 controls of European ancestry. Risk alleles were enriched in synaptic signalling pathways and brain-expressed genes, with 15 genes robustly implicated via gene expression analysis as potential druggable targets.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.